Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

With its latest acquisition, Lilly will carve out a spot in the PI3K inhibitors space in breast cancer, which for long was dominated by Novartis’ Piqray (alpelisib). In October 2024, Roche had a ...

Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...